Discovery and Validation of Barrett's Esophagus MicroRNA Transcriptome by Next Generation Sequencing by Bansal, Ajay et al.
Discovery and Validation of Barrett’s Esophagus
MicroRNA Transcriptome by Next Generation
Sequencing
Ajay Bansal1,2,3*, In-Hee Lee4., Xiaoman Hong5., Sharad C. Mathur2,6, Ossama Tawfik2,3,
Amit Rastogi1,2,3, Navtej Buttar7, Mahesh Visvanathan4, Prateek Sharma1,2,3, Lane K. Christenson3,5
1 Division of Gastroenterology and Hepatology, Veterans Affairs Medical Center, Kansas City, Kansas, United States of America, 2 University of Kansas Medical Center,
Kansas City, Kansas, United States of America, 3 Kansas Cancer Institute, University of Kansas Medical Center, Kansas City, Kansas, United States of America,
4 Bioinformatics Core Facility, University of Kansas, Lawrence, Kansas, United States of America, 5 Department of Molecular and Integrative Physiology, University of
Kansas Medical Center, Kansas City, Kansas, United States of America, 6 Department of Pathology, Veterans Affairs Medical Center, Kansas City, Kansas, United States of
America, 7 Department of Gastroenterology, Mayo Clinic, Rochester, Minnesota, United States of America
Abstract
Objective: Barrett’s esophagus (BE) is transition from squamous to columnar mucosa as a result of gastroesophageal reflux
disease (GERD). The role of microRNA during this transition has not been systematically studied.
Design: For initial screening, total RNA from 5 GERD and 6 BE patients was size fractionated. RNA ,70 nucleotides was
subjected to SOLiD 3 library preparation and next generation sequencing (NGS). Bioinformatics analysis was performed
using R package ‘‘DEseq’’. A p value,0.05 adjusted for a false discovery rate of 5% was considered significant. NGS-
identified miRNA were validated using qRT-PCR in an independent group of 40 GERD and 27 BE patients. MicroRNA
expression of human BE tissues was also compared with three BE cell lines.
Results: NGS detected 19.6 million raw reads per sample. 53.1% of filtered reads mapped to miRBase version 18. NGS
analysis followed by qRT-PCR validation found 10 differentially expressed miRNA; several are novel (-708-5p, -944, -224-5p
and -3065-5p). Up- or down- regulation predicted by NGS was matched by qRT-PCR in every case. Human BE tissues and BE
cell lines showed a high degree of concordance (70–80%) in miRNA expression. Prediction analysis identified targets that
mapped to developmental signaling pathways such as TGFb and Notch and inflammatory pathways such as toll-like
receptor signaling and TGFb. Cluster analysis found similarly regulated (up or down) miRNA to share common targets
suggesting coordination between miRNA.
Conclusion: Using highly sensitive next-generation sequencing, we have performed a comprehensive genome wide
analysis of microRNA in BE and GERD patients. Differentially expressed miRNA between BE and GERD have been further
validated. Expression of miRNA between BE human tissues and BE cell lines are highly correlated. These miRNA should be
studied in biological models to further understand BE development.
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Introduction
Chronic gastroesophageal reflux disease (GERD) is an impor-
tant risk factor for the development of Barrett’s esophagus (BE).
BE is the dominant pre-malignant lesion for esophageal adeno-
carcinoma [1]. The prevalence of GERD has increased substan-
tially over the past decade with weekly reflux symptoms increased
by ,50% and will significantly impact the future rates of BE [2].
Esophageal adenocarcinoma has already increased by 600% since
1975 [3] and the increasing prevalence of GERD and BE are
likely to worsen the rates of esophageal adenocarcinoma raising a
significant public health concern. Understanding factors that lead
to development of BE in 10–15% of GERD patients may allow for
the development of prevention strategies against this cancer by
timely detection and intervention. Molecular events underlying the
initiation of Barrett’s metaplasia are incompletely understood but
biological interactions between developmental signaling pathways
and morphogenetic factors appear to play key roles [4].
MicroRNA (miRNA) regulate 20–30% of the genome by binding
to the mRNA transcripts and promoting their degradation and/or
inhibition of translation [5,6]. Since a single miRNA can impact
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several hundred genes [5,6], miRNA can potentially impact
multiple signaling pathways and elicit large effects on a cell’s
phenotype integral to BE development.
To date, studies have focused on identifying miRNA associated
with BE progression [7,8,9,10,11,12,13,14] but miRNA differen-
tially expressed between GERD squamous epithelium and BE
columnar epithelium have not been systematically examined.
While it is unknown but it is plausible that miRNA could be logical
targets to study for causal relationships in BE development.
Additionally, miRNA can be targeted by inhibitors and mimetics
that opens novel therapeutic possibilities for BE prevention [15].
For the final goal of identifying miRNA that are not simply
associated with BE but are causal to the transformation of
squamous to columnar mucosa, high-throughput miRNA profiling
is an initial necessary step. To characterize the miRNA
transcriptome of BE, we used state of the art next generation
sequencing (NGS). NGS has several significant advantages over
previous methods such as reverse-transcription (RT) PCR arrays
and hybridization-based microarrays including high sensitivity
towards low abundant transcripts, excellent reproducibility and
possibility of discovering previously unknown miRNA [16]. Our
aim was to perform one of the first comprehensive investigations
into defining the miRNA transcriptome of well-characterized
GERD and BE patients and set the platform for further biologic
characterization of specific miRNA using cellular, animal and
more recently organotypic [17] models. In the study described
henceforth, we were able to profile the miRNA expression of
GERD and BE patients using rigorous methodology and have
identified several novel miRNA such as miR-708-5p, -3065-5p, -
944 and -224-5p to be associated with BE that were predicted to
regulate important developmental, inflammatory and metabolic
pathways.
Methods
Ethics Statement
The current study was approved by the Institutional Review
Board of the Veterans Affairs Medical Center, Kansas City. All
subjects provided written and signed informed consent. All
research was conducted in accordance with the principles outlined
in the Declaration of Helsinki.
Selection of GERD and BE patients
Patients with GERD and BE were selected from a prospective
tissue and serum repository (Clinical Trials.gov #
NCT00574327). The Institutional Review Board of the Veterans
Affairs Medical Center, Kansas City, Missouri, approved this
repository. Patients presenting to the endoscopy unit for evaluation
of reflux symptoms or screening/surveillance of BE were invited to
participate in the study. After signing informed consent, all
patients were required to fill a validated GERD questionnaire
[18]. Patients with inability to provide written informed consent,
advanced chronic liver disease, severe uncontrolled coagulopathy,
and prior history of esophageal or gastric surgery or BE ablation
were excluded from the repository.
The patients were defined to have GERD if they answered
affirmative to the presence of heartburn and/or regurgitation.
After endoscopic examination, GERD patients were further sub-
classified into those with erosive esophagitis (EE) and those without
(Non-erosive reflux disease, NERD). BE was defined as presence of
columnar lined esophagus at least 1 cm in length on endoscopy
with demonstration of intestinal metaplasia in biopsies. To
minimize misclassification, BE patients were biopsied only if they
had no evidence of active reflux disease i.e. erosions or ulcers in
the Barrett’s segment. Only those BE patients that did not have
dysplasia were included in the current study to minimize the
impact of dysplasia grade on miRNA expression. For the initial
high-throughput discovery phase with NGS, only patients with a
definitive diagnosis of GERD based on the presence of EE were
included. In the validation phase by qRT-PCR, patients with EE
as well as NERD were allowed. Research biopsies were obtained
as part of a standardized protocol for collection of specimens for
the tissue repository. Per protocol, in GERD patients, 2 biopsies
were obtained at 1 cm and 5 cm above the gastro-esophageal
junction. In BE patients, 2 biopsies were obtained every 2 cm of
the BE length. Immediately after procurement, each biopsy
specimen was divided into two halves- one half was randomly
selected to be fixed in 10% formalin for histopathological
evaluation while the other half was placed in RNAlater
preservative (Applied Biosystems, Foster City, CA) for miRNA
studies.
Histologic review, RNA extraction and quality control
4 mm thick sections were stained by hematoxylin and eosin and
reviewed by a single experienced gastrointestinal pathologist
according to the revised Vienna classification [19]. Specimens
were examined for the presence of intestinal metaplasia charac-
terized by the presence of histologically typical goblet cells. Total
RNA was extracted using Trizol as per manufacturer’s protocol
(Sigma, St. Louis, MO). Total RNA was quantified using a
NanoDrop-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE), and quality was assessed on an Agilent 2001
Bioanalyzer (Agilent Technologies, Santa Clara, CA) and only the
highest quality samples with RNA integrity number (RIN) of .8
were used for NGS. The RIN value (mean 6 SEM) for the
validation cohort (n = 67) was 6.960.7.
Next generation sequencing
Total RNA from GERD (n = 5) and BE (n = 6) patients was size
fractionated on Flash-PAGE gels and RNA (,70 nucleotides) was
then subjected to SOLiD 3 library preparation [20], (Cofactor
Genomics, St Louis, MO) SOLiD 3 sequencing using ligation-
based sequencing technology was completed to yield 35 nucleotide
reads. Reads with a minimum of 6-nucleotide adaptor sequence
with no ambiguous bases and the final trimmed length of at least
15 nucleotides were included for the final alignment analysis.
Median-based normalization was done. To determine the final
candidate miRNA, the following steps were undertaken.
Step 1: Alignment to reference genome. Read sequences
from NGS data were aligned into the latest version (v18) of
miRBase, a repository of up-to-date miRNA information of many
species including human. Alignment was performed using the
bowtie short-read aligner software (version 0.12.7) [21]. Bowtie has
been shown to be efficient [22] and has been successfully used in
previous studies [23]. A minimum trimmed length of at least 15
nucleotides after removal of the adaptor sequences was used as
previously done [11,22]. Reads were regarded to be mature
miRNA based on two conditions a) if the entire read sequence
mapped within a miRNA hairpin sequence consecutively with a
maximum of one mismatch and b) overlapped minimum of 7
bases to the mature miRNA. The hairpin sequence represents the
precursor miRNA sequences [24] and is a unique characteristic of
miRNA [25]. Reads that overlapped with multiple mature
miRNA were not counted [24]. Post alignment, the number of
read sequences aligned to each miRNA (read counts) was
calculated. After the initial mapping to miRBase, the unmapped
reads were mapped to the non-coding RNAs reported in
functional RNA database (fRNAdb version 3.4), the human
MicroRNA Associated with Barrett’s Esophagus
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reference genome version 19 downloaded from UCSC genome
browser (hg19) and E. coli genome allowing up to 3 mismatches.
Reads that were still unmapped were remapped to the miRBase
allowing 2–3 mismatches, but these reads were not used in the
analysis of differentially expressed miRNA.
Step 2: Normalization of Read Counts. Normalization was
done using the DESeq Bioconductor package in R [26] that takes
the total number of reads into consideration [27]. This was done
prior to the differential expression analysis to control for the
variation in the number of read sequences across samples. The
normalization method consisted of the following steps:
1) Construct a pseudo-reference by taking geometric mean of all
miRNA. That is, the value for i-th miRNA is calculated as
geometric mean of i-th miRNA in all samples.
1) k̂i~ Pj kij
 1=m
, where i = 1, …, n indexes the miRNA, j = 1,
…, m indexes the sample and kij denotes the counts for i-th
miRNA in j-th sample.
2) Estimate size-factor of i-th sample as the median of the ratios
of the i-th sample’s counts to those of the pseudo-reference’s.
ŝj~ median
i
kij
k̂ij
:
3) Divide the i-th sample’s counts by its size-factor to obtain
normalized counts.
k’ij~kij

ŝj :
Step 3: Differential Expression Analysis. After normalized
read counts were obtained, a state of the art statistical model for
NGS differential expression analysis ‘‘R’’ package called DESeq
[26] was used. DESeq is based on the negative binomial
distribution and outputs fold change and p-values for differential
expression. miRNA whose p-values (adjusted for false discovery
rate of 5%) ,0.05 were considered to be differentially expressed.
The standard R function p.adjust was used to adjust p-values for
multiple testing using the Benjamini-Hochberg method [28].
Validation of NGS results by quantitative RT-PCR analysis
in independent samples
Total RNA (50 gg) from an additional 40 GERD patients, and
27-BE patients were reverse transcribed using hairpin RT-primers
that matched our custom designed low-density qPCR array cards
(Applied Biosystems). Quantitative RT-PCR was conducted using
our established procedures [29,30]. SDS software (version 2.4,
Applied Biosystems) was used to identify threshold cycle (Ct) values
for each PCR reaction. Expression of the small nucleolar RNAU6
was used to normalize miRNA expression measurements, and
relative fold-changes of miRNA expression values between
samples were calculated using the delta-delta Ct method [29].
All samples were compared to a sample from a single patient in
order to calculate fold-changes. Each primer set included a minus
RT control. Standard t-test was used to test differential expression
of miRNA. MicroRNA with a p-value ,0.05 after adjusting for
the false discovery rate of 5% were labeled as differentially
expressed. The standard R function p.adjust was used to adjust p-
values for multiple testing using the same correction method as in
NGS analysis.
miRNA target prediction and pathway analysis
We searched the potential target genes of the miRNA and
mapped the signaling pathways related to the target genes. We
used multiple prediction programs including microT [31],
miRanda [32], miRTarget2 [33], PicTar [34], PITA [35],
RNA22 [36], and TargetScan [37]. To minimize the risk of false
positives, predictions of each program were filtered by using only
those scoring within the top 5%. Genes with strong prediction
scores for the same miRNA from at least 2 programs were labeled
as potential targets for that miRNA and used in pathway analysis.
But for miRNA with no target gene shared by multiple programs,
genes with prediction scores that ranked within the top 1% by any
program were used as potential target genes for the miRNA. We
used EGAN [38] to find KEGG pathways strongly associated with
the target genes.
miRNA expression in Barrett’s cell lines
After RNA extraction, we compared the ten highest and the
lowest expressed miRNA identified by NGS in human BE tissues
with three different BE human cell lines, BAR-T, CP-A and CP-C.
We performed this analysis to mutually validate the expression of
miRNA between human BE epithelium and well established BE
human cell lines and to identify appropriate cell lines for future
biological experiments of miRNA modulation to understand
miRNA function in BE development. BAR-T is a non-neoplastic
Barrett’s cell line created by hTERT immortalization of human
BE cells [39]. CP-A and CP-C are immortalized cell lines created
also from human Barrett’s biopsies [40,41]. CP-A expresses wild
type p53 whereas CP-C hosts p53 LOH and mutations. Both CP-
A and CP-C cells have p16 sequence alterations. Spearman’s
correlation coefficients for miRNA expression between human BE
tissues and cell lines were calculated.
Results
Study subjects
The initial NGS cohort consisted of 11 patients, five with
GERD (all with EE) and six with BE. All 11 patients were white
males with mean ages of 5464 and 6169 years respectively. After
initial NGS profiling, the miRNA were validated by qRT-PCR in
independent GERD (n = 40) and BE (n = 27) patients. Mean ages
were 55613 and 61610 years respectively. All patients were white
males and were on acid suppressive therapy. Mean BE length was
Prague [42] M563.1C3.161.5. Hiatus hernia was present in 63%
of GERD patients versus 95% of BE patients, p,0.05. Mean body
mass index BMI was similar in two groups, 3266.6 in GERD
versus 3067.7 in BE, p = NS. Among 40 GERD patients, 20 had
EE and 20 had NERD, mean ages 50614 and 59611 years
respectively, p = NS. All EE patients had Los Angeles classification
B or higher grade of esophagitis.
Discovery project and validation
NGS completed on BE patients (n = 6) and GERD (n = 5)
patients, yielded an average of 19.3 million raw reads/patient.
After removing adapter sequences and filtering out reads too short
to be accurately mapped (less than 15 bases), we obtained on
average 7.6 million reads/patient sample and 98.5% of them were
mapped to either miRBase, non-coding RNAs (fRNAdb), or
human reference genome version 19 (Figure 1).
53% of reads mapped to known miRNA in miRBase 18.0 with
either 0 or 1 mismatch (Figure 1). The remaining reads were
mapped to the non-coding RNA database excluding miRNA
(fRNAdb version 3.4) which accounted for 25.1% of the reads of
which rRNA accounted for 12%. Remaining reads were then
MicroRNA Associated with Barrett’s Esophagus
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mapped to the human genome version 19 that accounted for
8.19% of the reads. Remaining reads were also compared to the E.
Coli database and a very small fraction 0.013% of reads mapped
to that database. All of the unmapped reads were then remapped
to the miRbase allowing for two or three mismatches (13.66% of
total trimmed reads) leaving ,1% of the reads unmapped
(Figure 1). The majority of trimmed reads that mapped to miRNA
were 21–23 nucleotides in length as expected for the miRNA
(Figure 2A). Relative distribution of the reads into miRNA and
non-miRNA databases according to read length is shown in
figure 2B and again, as expected, a majority of miRNA alignment
with 0 or 1 mismatch occurred between 21–23 nucleotides in
length. Among 1921 known miRNA in miRBase 18, the number
of miRNA detected in our samples (non-zero read counts) ranged
from 736,1122/patient (919 miRNA/patient on average). The
complete list of miRNA with normalized read counts is described
in Table S1. Raw NGS expression data will be made available to
the investigators upon request.
Identification of differentially expressed miRNA between
GERD and BE patients
When we compared the GERD group with the BE group, 18
miRNA were differentially expressed based on DEseq FDR
adjusted p value of ,0.05 (Table 1). Of these 18 miRNA, four
miRNA (-miRs-4253, -4776-3p, -548n and -675-3p) had reads
,25 in each group and were excluded from the RT-PCR
validation step. Of the 14 miRNA included in the qRT-PCR
validation and evaluated in the larger cohorts of patient, all but
one (miR-551b-3p) were detectable by qRT-PCR. Of the 13
detected miRNA by RT-PCR, ten were significantly different
between the two groups (Table 1). Several of these miRNA are
new and not been previously described to be associated with BE,
such as miR-708-5p, -3065-5p, -944 and -224-5p. Of the 10
miRNA discovered by NGS and validated by qRT-PCR, three
were up-regulated (log2 fold change 5.9–6.8) and seven were
down-regulated (log2 fold change 2.9–6.2). Additionally, reassur-
ingly, there was 100% consistency in the direction of fold change
between NGS and RT-PCR datasets for all validated miRNA. In
other words, if a miRNA was found as up-regulated by NGS data,
it was also found to be up-regulated by RT-PCR and the same
principle was true for down-regulated miRNA. Upon subgroup
analysis, none of the evaluated miRNA were differentially
expressed between the EE and NERD groups (Table 2). We also
compared the BE group with the EE and the NERD subgroups
(Table 2). Similar miRNA were found to be differentially
expressed between the BE versus EE and the BE versus NERD
groups. There were minor differences in the degree of fold change
between the BE/EE and BE/NERD groups without any statistical
significance.
Genes targeted by the identified miRNA
Only those targets that scored in the top 5% of all predictions by
at least two different programs or scored in the top 1% by any one
program were included. Using these criteria, targets for the
differentially expressed miRNA between BE and GERD group
were identified (Table S2). These targets belonged to multiple
signaling pathways including TGFb, MAPK, Notch, mTOR,
WNT, hedgehog and PPAR, several of which regulate embryo-
logical development and differentiation. On further analysis,
several of the miRNA shared common targets and were similarly
up- or down regulated (Figure 3). For instance, miRs-3065, -149
and -944 shared common targets and were similarly downregu-
lated (Fig. 3A). Note that two of these, miR -3065 and -944 are
new and not previously described in association with BE.
Similarly, miR -192 and -215 shared common targets and were
both upregulated (Figure 3B). These miRNA-mRNA target
analyses suggest a coordinated interplay between several miRNA
in regulation of target genes that may play a role in the
development of BE and their role in BE genesis need to be
further validated.
miRNA expression in Barrett’s cell lines
We examined the expression of the ten most over- (miR-192-5p,
103a-5p, 145-5p, -215, -451a, -23b-3p, -21-5p, 23a-3p, 24-3p,
191-5p) and under- expressed (miR-491-3p, -574, -18a, -488-5p, -
216a, -548, -520d, -20b, -218, -346) human BE miRNA in three
BE cell lines, BAR-T, CP-A and CP-C. The mean number of
reads by NGS for the ten most expressed miRNA in human BE
specimens was 78178 (range 27,374–240,611). Of these 10
miRNA highly expressed in human BE tissues, eight were
expressed in the BAR-T cell line, mean Ct 25.7 (range 18–31)
and seven were expressed in CP-A and CP-C cell lines, mean Ct
Figure 1. Flowchart depicting sequential mapping of the reads.
As demonstrated, the unmapped reads were remapped to miRbase
after relaxing the criteria to allow 2–3 mismatches leaving only ,1% of
the reads unmapped. fRNAdb, functional RNA database version 3.4;
‘ambiguous’ represents those reads that mapped to multiple different
non-coding RNA in the fRNAdb; ‘others’ includes unclassified ncRNAs in
fRNAdb; * these miRNA were not included in the final analysis of
differential expression.
doi:10.1371/journal.pone.0054240.g001
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Figure 2. Normalized read counts and their distribution according to the nucleotide length. Fig. 1A shows that majority of trimmed reads
were 21–23 nucleotides in length, the same size as miRNA. Fig. 1B shows the distribution of trimmed reads based on their mapping to miRNA, human
genome, non-coding RNA (besides miRNA etc) and E coli genome. mm1, mm2 and mm3 represent alignment to miRBase with 0 or 1, 2 and 3
mismatches respectively. Note that the majority of aligned miRNA with 0 or 1 mismatch are distributed around 22 base pairs, the expected size of
miRNA. hg19, human genome version 19; fRNAdb, functional RNA database.
doi:10.1371/journal.pone.0054240.g002
Table 1. Differential expression of miRNA between BE and GERD.
miRNA Discovery phase (NGS) Validation phase (RT-PCR)
Fold change1 (BE/GERD) p-value2 Fold change3 (BE/GERD) p-value2
hsa-miR-194-5p 6.83 9.11E-08 6.5 2.18E-14
hsa-miR-215 5.85 1.78E-06 9.6 1.30E-12
hsa-miR-205-5p -4.72 2.06E-05 210.0 4.35E-11
hsa-miR-192-5p 5.58 3.99E-05 7.6 4.05E-16
hsa-miR-203 -4.73 3.99E-05 24.4 1.97E-15
hsa-miR-944 -6.24 8.44E-04 210.1 3.80E-11
hsa-miR-224-5p -3.37 1.27E-03 27.9 3.72E-07
hsa-miR-708-5p -3.66 2.39E-03 23.7 6.21E-07
hsa-miR-338-3p 4.28 2.83E-03 1.67 1.0
hsa-miR-149-5p -2.88 2.83E-03 24.4 2.46E-12
hsa-miR-1260b -3.41 3.43E-03 20.79 0.07
hsa-miR-551b-3p 4.22 3.43E-03 ND NA
hsa-miR-3065-5p -3.9 0.01 21.8 0.001
Has-miR-196a-5p 3.97 0.03 0.08 1.0
NGS, next generation sequencing; BE, Barrett’s Esophagus, GERD, Gastroesophageal reflux disease; negative numbers indicate downregulation in BE compared to GERD;
1fold changes were expressed as log2 values;
2p-value was adjusted for false discovery rate of 5%;
3fold change by RT-PCR calculated by DDCt method;
miRs-4253, -4776-3p, -548n and -675-3p were also significantly different but with reads ,25 in each group and were not included for RT-PCR validation.
doi:10.1371/journal.pone.0054240.t001
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cycles 24.9 (range 17–31) and 24.7 (18–30) respectively. miR-215
that was highly expressed in human BE tissues was expressed only
in the BAR-T cell line. The mean number of copies by NGS for
the ten most under-expressed miRNA in human BE specimens
was 1.04 (range 1.00–1.05). Seven of these were not detected in
any of the three cell lines, all Ct greater than 40. The correlation
coefficients for miRNA expression with human BE tissues were
higher for BAR-T than the CP-A and CP-C cell lines, Spearman’s
rho 20.71, 20.59 and 20.55 respectively, all p,0.05, negative
sign denotes inverse relationship between copy number and Ct
cycle. Thus, there was a significant degree of concordance in
miRNA expression between human BE tissues and BE human cell
lines.
Discussion
MicroRNA can regulate multiple genes and impact multiple
cellular processes including cell fate and differentiation [6,43] and
likely regulate the development of BE. To the best of our
knowledge, this is the first study that has comprehensively
examined the GERD and BE miRNA transcriptome using
NGS. This study not only confirmed previously known BE
associated miRNA shown in small studies, we also discovered new
miRNA potentially associated with the initiation and development
of BE. To this effect, we have established a list of miRNA up- and
down-regulated between well-defined GERD and BE patients
from a prospective tissue repository. We did not observe significant
differences in fold changes of miRNA when BE patients were
compared with the GERD subgroups, EE and NERD. Our
findings that majority of differentially expressed miRNA were
down-regulated in BE is consistent with the proposed role of
miRNA as oncosuppressors and their consequent downregulation
in neoplasia [44]. Additionally, the miRNA expression of BE
patients correlated well with that of BE cell lines suggesting that
these cell lines may be useful to further understand the role of
miRNA in BE pathogenesis. Differentially expressed miRNA
discovered in this study target genes that map to pathways
important in embryological development and differentiation such
as TGFb, Notch, WNT, hedgehog; inflammation such as toll-like
receptor signaling, TGFb, T cell receptor signaling, chemokine
signaling pathway; metabolism and survival such as mTOR;
homeostatic signaling such as MAPK and lipid homeostasis such
as PPAR (Table S2). Also, similarly up-regulated and down-
regulated miRNA shared common targets suggesting coordination
between miRNA in regulation of BE development. These miRNA
should be studied further to elucidate specific miRNA regulated
molecular mechanisms that lead to the development of BE in a
subset of patients with chronic GERD.
Previous studies by our group and others evaluating miRNA
expression in BE have focused on identification of the miRNA
associated with the progression of BE to dysplasia and adenocar-
cinoma [7,8,9,10,11,12,13,14]. These studies have identified
several miRNA that are associated with the development of BE
neoplasia. However, none of the studies have focused on systemic
identification of miRNA associated with the squamous to
columnar switch as seen in GERD patients who harbor BE. A
few studies evaluated both dysplastic and non-dysplastic patients
and compared them with controls using hybridization arrays and
found several differentially expressed miRNA such as miR-215, -
192, and miR-205 [8,45]. Another study that compared select
miRNA between paired squamous and columnar tissues from
seven BE patients found miR-215 and -192 to be upregulated and
miR-203 and -205 to be downregulated in the columnar
epithelium [46]. Our NGS dataset not only confirmed the
significantly different expression of miR-215, -192, -203 and -
205 between GERD and BE but took a more comprehensive
approach to identify several novel miRNA not previously
described in BE, such as miR-708, -944, -224-5p, -3065-5p
among others. Some of the miRNA identified in the current study
have relatively low copy numbers (footnote Table 1) and thus,
were uniquely identified by NGS but likely missed by microarrays
due to lower sensitivity [16]. However, at this point, the
relationship between copy numbers and their biologic relevance
is unclear. Since a miRNA can regulate several hundred genes, a
miRNA with small copy numbers could still have a significant
effect on cellular processes.
We also compared the expression of the ten most over- and
under- expressed miRNA in human BE tissues with three BE cell
lines, BAR-T, CP-A and CP-C. There was a high degree of
concordance between the miRNA expression in human BE tissues
and three distinct BE cell lines. 70–80% of the over-expressed
human BE miRNA were also expressed in the three BE cell lines
(all Ct ,31) and 70% of the least expressed human BE miRNA
were not detected in any of the BE cell line (all Ct .40). miR-215
that was highly expressed in human BE tissues was expressed only
in the BAR-T cell line, perhaps suggesting BAR-T to be a good
cell line for biological experiments of miRNA modulation to
further understand the pathways associated with BE pathogenesis.
The role of miRNA in the origin of BE remains under-evaluated
but is plausible. Direct evidence for the important role of miRNA
in maintenance of columnar epithelia comes from mice with the
intestine specific knockout of Dicer [47], an enzyme obligatory for
miRNA processing. In these mice, the intestinal epithelium was
disorganized with decrease in goblet cells and increased intestinal
Table 2. Differentially expressed miRNA in BE compared to
the GERD subgroups, EE and NERD.
miRNA
BE/EE
Fold change1
(p-value2)
BE/NERD
Fold change1
(p-value2)
EE/NERD
Fold change1
(p-value2)
hsa-miR-194-5p 7.1 (1.39E-11) 5.9 (3.70E-06) 21.2 (1.0)
hsa-miR-215 9.8 (1.34E-07) 9.1 (3.85E-05) 20.6 (1.0)
hsa-miR-205-5p 29.7 (1.85E-10) 210.2 (3.95E-11) 20.5 (1.0)
hsa-miR-192-5p 8.8 (4.33E-10) 6.4 (9.80E-07) 22.5 (0.87)
hsa-miR-203 24.2 (1.48E-14) 24.6 (2.19E-15) 20.4 (1.0)
hsa-miR-944 210.1 (2.47E-11) 210.1 (2.15E-11) 20.05 (1.0)
hsa-miR-224-5p 27.6 (1.07E-06) 28.2 (1.86E-07) 20.6 (1.0)
hsa-miR-708-5p 23.5 (8.07E-06) 24.0 (7.26E-07) 20.5 (1.0)
hsa-miR-338-3p 1.8 (1.0) 1.6 (1.0) 0.2 (1.0)
hsa-miR-149-5p 23.9 (4.33E-10) 24.9 (1.48E-08) 20.97 (1.0)
hsa-miR-1260b 20.75 (0.4) 20.83 (0.13) 20.07 (1.0)
hsa-miR-551b-3p ND ND ND
hsa-miR-3065-5p 21.4 (0.03) 22.2 (0.002) 20.74 (1.0)
hsa-miR-196a-5p 0.23 (1.0) 0.07 (1.0) 20.31 (1.0)
BE, Barrett’s esophagus; GERD, Gastroesophageal reflux disease; EE refers to
those GERD patients with erosive esophagitis; NERD (Non-erosive reflux
disease) refers to those GERD patients without erosive disease; NGS, next
generation sequencing; negative numbers indicate downregulation in BE
compared to GERD;
1Fold changes by RT-PCR calculated by DDCt method;
2p-value was adjusted for false discovery rate of 5% and reported in
parentheses; miRs-4253, -4776-3p, -548n and -675-3p were also significantly
different but with reads ,25 in each group and were not included for RT-PCR
validation; ND, not detected.
doi:10.1371/journal.pone.0054240.t002
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inflammation. A recent study over-expressed miR-145 in Het-1A
and BAR-T cells and showed changes in expression of important
BE related genes such as BMP4 and provide rationale for miRNA
involvement in BE development [45]. Software based prediction
analysis of targets for the differentially expressed miRNA in this
study mapped to multiple signaling pathways related to develop-
ment and inflammation such as TGFb [48], MAPK, Notch,
mTOR, WNT, hedgehog, PPAR, Toll like receptor chemokine
signaling several of which have been implicated in the origin of BE
[49,50]. Interestingly, miRNA-944, a novel miRNA detected in
this study regulates HOXB5 (Table S2). HOXB5 is a transcription
factor of the homeobox family that has recently been experimen-
tally validated to regulate BE development [51]. Cluster analysis
found multiple similarly regulated (up or down) miRNA to share
common targets suggesting a coordinated interplay between
miRNA in regulation of BE development (Figure 3). The majority
(7/10) of validated miRNA in the current study were down-
regulated in BE compared to GERD suggesting that squamous to
columnar phenotype is associated with activation of previously
repressed genes. MicroRNA have also been shown to modulate
cellular differentiation in other organ systems [52,53]. There are
several competing theories for the origin of BE, the two prominent
ones being transdifferentiation of the squamous cells [4] versus
repopulation of the distal esophagus from the embryonic precursor
cells at the squamocolumnar junction [54]. In both of these
models, there are regulating factors other than the cell of origin
that lead to the metaplastic change of BE in a subset of GERD
individuals. Supported by significant differences in miRNA
profiles between the GERD and BE population, we propose that
the miRNA may regulate development of BE and need to be
further evaluated. Previous studies have demonstrated the
feasibility of molecular diagnosis of BE by measurement of Trefoil
factor 3 expression on cytology specimens [55]. MicroRNA
expression appears to be highly discriminative between GERD
and BE patients and can similarly be useful for the molecular
diagnosis of BE. Whether these miRNA can be also used as
molecular markers of cancer progression remains to be seen.
The three commonly used methods for high-throughput
miRNA analysis are RT-PCR arrays, hybridization-based micro-
array and NGS. RT-PCR arrays can only detect known miRNA.
Hybridization based technologies are limited by issues related to
probe design and array background [16]. NGS does not require
Figure 3. Prediction of target genes for similarly regulated miRNA. Note that miR -3065, -944 and -149-5p all were down-regulated and
share multiple common targets (Panel A) and miR-192 and -215 all were up-regulated and share common targets (Panel B). These results of common
targets for similarly up- or down- regulated miRNA suggest coordination between miRNA.
doi:10.1371/journal.pone.0054240.g003
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prior knowledge of small RNA transcripts [16], allows discovery of
other non-miRNA small RNA molecules such as Piwi-interacting
RNAs [5]. NGS has high sensitivity towards low abundance
transcripts and excellent reproducibility. A limitation of NGS [56]
is that miRNA copy numbers depend on the method used for
RNA library preparation [57]. However, NGS is a highly robust
method for comparing relative abundance of miRNA copies across
samples since any biases introduced by the preparation method
are highly systematic [57]. An important determinant of the
usefulness of a high-throughput methodology is its validation by
standardized techniques. The validation rate for our NGS data by
qRT-PCR was ,70%, significantly higher than a rate of 30–40%
reported for miRNA hybridization microarrays [58].
Our study does have limitations but we believe that they do not
alter our interpretation. The sample sizes for the discovery phase
were relatively small. Sample size calculations for NGS are not
well defined and are dictated by cost constraints as practiced in
other NGS studies [59,60]. We would like to emphasize that close
to three-fourths of the differentially expressed miRNA discovered
by NGS were validated by qRT-PCR (adjusted for multiple
testing) with direction of fold change matched in every case and
attests to the robustness of our procedures for NGS analysis. The
average alignment rates of the NGS datasets in this study were
somewhat lower. However, this has also been noted in other
studies on cervical cancer where both patient specimens and cell
lines were sequenced and could be explained on the basis of some
cellular damage during the acquisition of clinical specimens [59].
However, the alignment rates were not significantly different
between the GERD and BE samples and would not affect the
differentially detected miRNA. Barrett’s biopsies may contain
more stroma than squamous biopsies but still such biopsies are
predominantly (,90%) composed of epithelial cells as suggested
by previous flow cytometry studies [61]. pH monitoring was not
performed to confirm GERD. However, a validated GERD
questionnaire was used at the time of recruitment. Moreover, pH
monitoring is not practical as part of patient enrollment into a
tissue repository and could discourage subject participation with
potential for recruitment bias.
In summary, the current study has discovered and validated the
miRNA transcriptome of GERD and BE patients by next
generation sequencing. The results validated previously described
miRNA as well as discovered novel miRNA in BE and provide a
comprehensive list of miRNA to be the subject of future molecular
research into the pathogenesis of BE using animal and cellular
models. The target genes and the pathways being regulated by the
identified miRNA need to be further deciphered.
Supporting Information
Table S1 The table lists complete list of miRNA identified by
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